Malignant melanoma of the mucous membranes: A review of 119 cases

Citation
P. Dematos et al., Malignant melanoma of the mucous membranes: A review of 119 cases, ANN SURG O, 5(8), 1998, pp. 733-742
Citations number
78
Categorie Soggetti
Oncology
Journal title
ANNALS OF SURGICAL ONCOLOGY
ISSN journal
10689265 → ACNP
Volume
5
Issue
8
Year of publication
1998
Pages
733 - 742
Database
ISI
SICI code
1068-9265(199812)5:8<733:MMOTMM>2.0.ZU;2-1
Abstract
Background: Melanomas arising from the mucous membranes lining the respirat ory, digestive, and genitourinary tracts are rare. Women are more commonly affected than are men, mainly because there is no male counterpart for vulv ovaginal lesions. The mainstay of therapy is surgery, with little current u se of adjuvant modalities in primary therapy. These lesions usually are adv anced at initial presentation; consequently, the prognosis is poor, with 5- year survivals well below 50% in most series. Methods: One hundred and nineteen patients with primary mucosal melanoma we re reviewed. They represented 1.1% of the 10,393 melanoma patients seen at Duke University between 1970 and 1995. All data were obtained from the pati ents' clinic charts and computerized databases. Results: There were 43 tumors arising from the head and neck region, 46 fro m the urogenital tract, and 30 from the anorectum. A female predominance wa s observed, with a female-to-male ratio of 2.7 : 1. All but five of the pat ients underwent resection with curative intent. Regional or distant metasta ses, or both, were encountered in 36 patients at the time of presentation. In patients with head and neck and urogenital tumors, local recurrences acc ounted for most of the treatment failures, whereas systemic recurrences wer e more common with tumors arising in the anorectum. The age and gender of t he patient, anatomic site of origin of the tumor, clinical stage at initial presentation, and ulceration of the primary all clearly affected prognosis . Overall, the probabilities of being alive 1, 5, and 10 years after diagno sis were 80%, 29%, and 15%, respectively. Conclusions: Widely accepted classification systems are needed so that resu lts from separate institutions can be compared adequately. Multi-institutio nal trials could help in delineating standardized therapeutic protocols and in establishing the potential roles of emerging modalities in the treatmen t of this subtype of melanoma.